First patient dosed in Phase 1/2 trial of CHM CDH17
Filed with ASX · · 3 pages · English
• The first-in-human clinical trial of CHM CDH17 is recruiting subjects at US Cancer Centres with advanced colorectal cancer, gastric cancer and intestinal neuroendocrine tumours • First patient dosed at Sarah Cannon Research Institute in Nashville, Tennessee Sydney, Australia, 28 August 2024: Chimeric Therapeutics (ASX:CHM, “Chimeric” or the “Company”), an Australian leader in cell therapy, is pl
Chimeric Therapeutics Limited on 6ix
Earlier from Chimeric Therapeutics
- First patient enrolled in CHM CDH17 Phase 1/2 clinical trial
- Phase 1b ADVENT-AML trial of CHM CORE-NK advances at MDA
- Chimeric opens CHM CDH17 Phase 1/2 trial
- CHM CDH17 Phase 1/2 clinical trial approved for initiation
- Resignation of CEO and Managing Director
Later from Chimeric Therapeutics
- Appendix 4E and Preliminary Final Report
- AML patient achieves Complete Response in CHM CORE-NK trial
- $5 million Placement to progress CHM CDH17 trial
- Reinstatement to Official Quotation
- AGM Presentation and CEO Appointment
Follow Chimeric Therapeutics into a list and get an email when it puts out news.
Follow Chimeric Therapeutics